文献速递糖尿病

加州大学五大医疗系统2型糖尿病治疗利用差异的量化研究

Quantifying Variation in Treatment Utilization for Type 2 Diabetes Across Five Major University of California Health Systems.
PubMed 文献 · Diabetes Care · 2021-02-02

该回顾性分析利用加州大学健康数据仓库2014-2019年电子病历,纳入97,231例2型糖尿病患者,比较五大分校医疗系统及个体医生间的降糖治疗利用差异。研究发现医疗系统间及医生间在治疗强化、同类药物选择及心血管保护药物使用上存在显著差异,展示了电子病历量化治疗差异以推动精准医疗标准化的潜力。

要点

  • 医疗系统间及医生间在指南内治疗强化模式存在显著差异。
  • 同一药物类别内(如磺脲类)的药物选择差异显著。
  • 部分医生对高心血管风险患者更频繁使用心血管保护药物,而少数则较少使用。

核心结论

  • 医疗系统间及个体医生间在2型糖尿病降糖治疗利用上存在显著差异。
  • 电子病历结合队列匹配技术可量化治疗差异,为标准化精准医疗提供依据。

研究设计与样本

  • 回顾性分析,使用加州大学健康数据仓库2014-2019年去标识化电子病历,纳入97,231例2型糖尿病患者,来自1,003个附属临床机构。
  • 采用二项概率与队列匹配方法识别医疗系统间及医生间的显著差异。

主要发现

  • 在二甲双胍单药或二甲双胍联合磺脲类基础上按指南强化治疗方面,发现医疗系统间21处差异、医生间29处差异。
  • 同类药物选择(如格列吡嗪vs格列本脲)方面,发现医疗系统间33处差异、医生间86处差异。
  • 2个医疗系统和55名医生对高心血管风险患者更频繁使用心血管保护药物,而1个医疗系统和8名医生使用较少。

临床怎么用

  • 提示需关注医疗系统及医生层面治疗利用的变异性,以推动精准医疗标准化。
  • 可利用电子病历数据识别并减少不合理的治疗差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Using the newly created University of California (UC) Health Data Warehouse, we present the first study to analyze antihyperglycemic treatment utilization across the five large UC academic health systems (Davis, Irvine, Los Angeles, San Diego, and San Francisco). RESEARCH DESIGN AND METHODS: This retrospective analysis used deidentified electronic health records (EHRs; 2014-2019) including 97,231 patients with type 2 diabetes from 1,003 UC-affiliated clinical settings. Significant differences between health systems and individual providers were identified using binomial probabilities with cohort matching. RESULTS: Our analysis reveals statistically different treatment utilization patterns not only between health systems but also among individual providers within health systems. We identified 21 differences among health systems and 29 differences among individual providers within these health systems, with respect to treatment intensifications within existing guidelines on top of either metformin monotherapy or dual therapy with metformin and a sulfonylurea. Next, we identified variation for medications within the same class (e.g., glipizide vs. glyburide among sulfonylureas), with 33 differences among health systems and 86 among individual providers. Finally, we identified 2 health systems and 55 individual providers who more frequently used medications with known cardioprotective benefits for patients with high cardiovascular disease risk, but also 1 health system and 8 providers who prescribed such medications less frequently for these patients. CONCLUSIONS: Our study used cohort-matching techniques to highlight real-world variation in care between health systems and individual providers. This demonstrates the power of EHRs to quantify differences in treatment utilization, a necessary step toward standardizing precision care for large populations.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Peterson TA, Fontil V, Koliwad SK, et al. Quantifying Variation in Treatment Utilization for Type 2 Diabetes Across Five Major University of California Health Systems. Diabetes Care. 2021. PMID: 33531419. doi:10.2337/dc20-0344

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。